Skip to content

The FundoRingOAGB Versus Non-wrapping (Non-banded) Standard Method of Laparoscopic One Anastomosis Gastric Bypass

The Total Wrapping of the Fundus of the Gastric Excluded Part (FundoRing) Versus Non- Wrapping (Non-banded) Standard Method of Laparoscopic One Anastomosis Gastric Bypass/Mini - Gastric Bypass: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04834635
Acronym
FundoRingMGB
Enrollment
1000
Registered
2021-04-08
Start date
2021-03-29
Completion date
2024-12-31
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Morbid

Keywords

Obesity, Bariatric surgery, One anastomosis gastric bypass, FundoRingOAGB, Fundoplication

Brief summary

Currently, one anastomosis gastric bypass (OAGB) or mini-gastric bypass (MGB) is a common bariatric procedure for treating obesity. Weight gain after surgery is a big problem in bariatric practice. Therefore, adjustable bands and rings are used, for example, "FobiRing". But foreign material can cause complications - the erosion of the stomach wall. For this reason, surgeons avoid the use of various mechanical devices on living tissues. The greatest criticism is of the OAGB for the likelihood of biliary reflux. In case of reflux of bile into the esophagus after surgery, as a rule, a second operation is required with conversion OAGB to the Roux-en-Y method. In addition, along with obesity, gastroesophageal reflux disease (GERD) are steadily increasing world weight and antireflux surgery must be performed simultaneously with bariatric surgery in obese patients. In these cases, most often in bariatric practice, hiatus cruroraphy is performed, and less often fundoplication using the fundus of the excluded part of the stomach. We hypothesize that total fundoplication can not only treat GERD but also significant prevent the return of weight like after a banded gastric bypass and prevent postoperative bile reflux in the esophagus. The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms. Methods: Adult participants (n=1000) are randomly allocated to one of two groups: Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group).

Detailed description

One anastomosis Gastric Bypass/Mini Gastric Bypass (OAGB/MGB) is gaining popularity as a primary surgical treatment for morbid obesity. The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms. Methods: Adult participants (n=1000) are randomly allocated to one of two groups: Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group). All patients are then followed up 12, 24, 36 months after surgery where record the changing body mass index and and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.

Interventions

PROCEDUREFundoRingOAGB

laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia

PROCEDUREOAGB

laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia

Sponsors

The Society of Bariatric and Metabolic Surgeons of Kazakhstan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* BMI from 30 to 50 kg / m2. * The person is generally fit for anesthesia (ASA grading 1-2) and surgery. * The person commits to the need for long-term follow-up.

Exclusion criteria

* BMI less than 30 kg / m2 and more than 50 kg / m2. * Prosthetic (mesh) Hiatal herniorrhaphy or large hiatal hernia; * Esophageal shortening * Los Angeles Classification of Oesophagitis (LA grade) C or D reflux esophagitis * History of surgery on the stomach or esophagus * Less than 18 or more than 60 years of age * Not fit for bariatric surgery * Psychiatric illness * Patients unwilling or unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change of body mass indexBaseline, at 12, 24, 36 months after surgeryThe measure is assessing a change of body mass index (kg/m2) in groups . Weight (kg) and height (cm) will be combined with the report of measurement by body mass index (BMI) kg/m2.
Number of participants with bile reflux in esophagusat 12, 24, 36 months after surgeryEndoscopic assessment of bile reflux in esophagus and 24-hour pH-impedance monitoring to detect number of postoperative esophageal bile reflux (non-acid reflux) in in each group
Number of participants with GERD symptomsBaseline, 12, 24, 36 months after surgeryChange of GERD symptoms (use GERD Health-related Quality of Life (GERD-HRQL) Questionnaire) if present GERD or number of participants with postoperative de Novo GERD. Scoring Scale 0 = No symptoms 1. = Symptoms noticeable but not bothersome 2. = Symptoms noticeable and bothersome but not every day 3. = Symptoms bothersome every day 4. = Symptoms affect daily activities 5. = Symptoms are incapacitating - unable to do daily activities
Frequency of late (>30 day) postoperative complication in each groups>30 days, at 12, 24, 36 months after surgeryNamber participants with late postoperative complication ( dumping syndrome, marginal ulcer, food intolerance, protein malnutrition, anemia, thiamine deficiency)
Chance of the components of Metabolic Syndrome (MetS) after surgerybaseline, 1 and 3-year follow-upChance of level of HbA1c (\<5,7%), level of HOMA-IR (\<2.7) , \< number participants with type 2 diabetes and arterial hypertension and chanqe of Lipid profile (Total Cholesterol: \<200 mg/dL, LDL Cholesterol: \<100 mg/dL (optimal), HDL Cholesterol: \>60 mg/dL (desirable), Triglycerides: \<150 mg/dL) at 1 and 3-year follow-up.

Secondary

MeasureTime frameDescription
Oral glucose tolerance testsBlood samples for glucose collects at 0, 15, 30, 60, 120, 150 and 180 minutes, while those for insulin collects at 0, 30, 60, 120 and 180 minutesA standard 3-hour oral glucose tolerance tests performs using 75 g glucose
Sigstad score6, 12, 24, 36 months after surgerySigstad score for questionnaire of diagnostic the dumping syndrome. The Sigstad score is a diagnostic index for dumping syndrome, with a score \>7 indicating a high probability of the condition, while a score \< 4 suggests alternative diagnoses. Key Elements of the Sigstad Scoring System: * Thresholds: \< or =3 (Negative), 4-7 (Doubtful), \>7 (Positive for dumping). * Key Symptoms Evaluated: Shock (+5), almost fainting/syncope (+4), desire to lie/sit down (+4), sweating/pallor (+4), palpitations (+2), nausea, and abdominal fullness.

Countries

Kazakhstan

Contacts

PRINCIPAL_INVESTIGATOROral Ospanov

President of Society of Bariatric and Metabolic Surgeons of Kazakhstan" (SBMSK)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026